You're using an outdated browser. Please upgrade to a modern browser for the best experience.
CAR-T Cells Shoot for New Targets: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Amina Yu and Version 1 by Katsiaryna Marhelava.

Chimeric antigen receptor (CAR)-T cell therapy is undeniably a promising tool in combating various types of hematological malignancies. However, it is not yet optimal and a significant number of patients experience a lack of response or relapse after the treatment. Therapy improvement requires careful analysis of the occurring problems and a deeper understanding of the reasons that stand behind them.

  • CAR-T cells
  • adoptive immunotherapy
  • CD19 antigen

1. Clinically Available CAR-T Therapies

Currently, there are four different CD19-targeting, and one BCMA-targeting Chimeric antigen receptor (CAR)-T products, approved by American and European Drug Agencies (Food and Drugs Administration and European Medicines Agency, respectively). All these products are used for the treatment of malignancies derived from abnormal B cells at different stages of their differentiation.
The general structure of a CAR construct includes four parts: (1) an extracellular antigen-binding domain, (2) a hinge, (3) a transmembrane helix, and (4) an intracellular signaling domain. Accordingly, decades of research in the area of CAR design have led to the development of five CAR-T cell generations, each of them differing in an intracellular signaling milieu composition. In fact, the first CAR-T generation contains only a single immunoreceptor tyrosine-based activation motif (ITAM) domain derived from a CD3ζ chain of the T cell receptor (TCR). Further approaches have involved adding one (second generation) or two (third generation) co-stimulatory domains (mostly CD28 and/or 4-1BB) that enhance CAR-T cells activation and persistence [8,9,10][1][2][3]; however, in order to additionally boost the CAR-T cells activation, proliferation, and killing potential, fourth and fifth CAR-T generations were designed [11][4]. Such CAR-T cells are armored with additional intracellular domains responsible for specific cytokines production (e.g., IL-12, IL-2). These CAR-T cells are currently being evaluated in the research phase.
CAR-T cells products used for therapy of hematological patients represent the second CAR-T cell generation, with either a CD28 or 4-1BB (CD137) co-stimulatory domain. Since 2017, four CAR-T cell products aimed to target CD19 were approved based on pivotal phase 1/2 clinical trials, all of which are still active. Initial clinical responses for each trial and appropriate follow-up studies results (with observations lasting longer than 2 years) are summarized in Table 1.
Table 1.
Clinically approved CAR-T therapies in B cell and plasma cell-derived malignancies.
Generic Name and Brand Name Indication Target

(Single Chain Variable Fragment, scFv)		 Signaling

Domain/

Hinge and TM		 Gene Editing Vector First

FDA/EMA

Registration Date		 Approval-Based Clinical Trials, Number of

Participants		 CR or ORR Rate Long-Term

Follow-Up

Studies,

Number of

Participants		 Survival

(Median

Follow-Up in Years)
Tisagenlecleucel

(KYMRIAH)		 R/R pediatric and YA B-ALL CD19

(FMC63)		 4-1BB-CD3ζ/CD8α Lentivirus August 2017/

August 2018		 ELIANA, n = 75 [NCT02435849] [12][5] CR 60% NCT01593696, n = 50

[13][6]		 median OS

10.5 months

(4.8 years)
R/R adult DLBCL May 2018/

August 2018		 JULIET, n = 93 [NCT02445248] [14][7] CR 40% JULIET follow-up,

n = 115 [15][8]		 median OS

11.1 months

(3.4 years)
Axicabtagene

Ciloleucel

(YESCARTA)		 R/R adult DLBCL

(including DLBCL

arising from FL)		 CD19

(FMC63)		 CD28-CD3ζ/CD28 Retrovirus October 2017/

August 2018		 ZUMA-1, n = 101

[NCT02348216] [16][9]		 CR 54% ZUMA-1 follow up, n = 101 [17][10] median OS

25.8 months

(4 years)
R/R adult PMBCL
R/R adult FL Mar 2021/

not yet

registered		 ZUMA-5, n = 84

[NCT03105336] [18][11]		 CR 79% not yet

available		 not yet

available
Brexucabtagene

Autoleucel

(TECARTUS)		 R/R adult

MCL		 CD19

(FMC63)		 CD28-CD3ζ/CD28 Retrovirus July 2020/

December 2020		 ZUMA-2, n = 60 (efficacy group) [NCT02601313] [19][12] CR 67% not yet

available		 not yet

available
R/R adult

B-ALL		 October 2021/

not yet registered		 ZUMA-3, n = 55

[NCT02614066] [20][13]		 CR 56% not yet

available		 not yet

available
Lisocabtagene

Maraleucel

(BREYANZI)		 R/R adult DLBCL

(including DLBCL

arising from indolent lymphoma)		 CD19

(FMC63)		 4-1BB-CD3ζ/IgG4 and CD28 Lentivirus May 2021/

pending registration		 TRANCEND NHL 001,

n = 256 [NCT02631044]

[21][14]		 CR 53% TRANCEND

NHL 001 follow-up, n = 257 [22][15]		 median OS

27.3 months

(2.4 year)
R/R adult PMBCL
R/R FL3B
Idecabtagene

Vicleucel

(ABECMA)		 R/R MM BCMA 4-1BB-CD3ζ/CD8α Lentivirus Mar 2021/

August 2021		 KarMMa, n = 100 (efficacy group) [NCT03361748] [23,[1624]][17] ORR 72%

sCR 28%		 not yet

available		 not yet

available
Note: Above 2 years of follow-up was considered long-term. Abbreviations: B-ALL—B cell acute lymphoblastic leukemia, CR—complete response, DLBCL—diffuse large B cell lymphoma, FL—follicular lymphoma, FL3B—follicular lymphoma grade 3B, MCL—mantle cell lymphoma, MM—multiple myeloma, ORR—overall response rate, OS—overall survival, PMBCL—primary mediastinal large B cell lymphoma, R/R—relapse/refractory, sCR—stringent complete response, YA—young adults.
Out of these four products only tisagenlecleucel (Kymriah) is registered for children and young adults (up to 25 years old) with B-ALL, who are refractory to previous treatment regimens, or with more than two relapses. Considering that it was the first CAR-T cell therapy approved, there is the longest follow-up available for this product (median 4.8 years), showing complete response (CR) in more than 60% of the patients and overall survival (OS) equal to 10.5 months [13][6]. On the other hand, the access to CD19-targeted CAR-T therapy for adult r/r B-ALL patients was not granted until recently, when in October 2021 the FDA approved brexucabtagene autoleucel (Tecartus) for such indication. The registration was based on the multicenter ZUMA-3 trial [20,25][13][18]. The efficacy estimation group in the phase 2 ZUMA-3 trial included 55 adult previously treated patients, of which 27% represented a high-risk group, bearing BCR-ABL1 translocation [20][13]. CR was achieved in 56% of the patients, and more importantly, CR or complete remission with incomplete hematological recovery (CRi) was reached in 60% of the patients previously submitted to blinatumomab, another CD19-targeted immunotherapy. The side effects post CAR-T infusions were generally manageable. Taking into consideration the combined results of phases 1 and 2, the median duration of remission in this trial was estimated by the investigators at 13.4 months; however, a longer follow-up is needed to draw stronger conclusions regarding safety profiles and the durability of responses.
In addition to adult B-ALL, brexucabtagene autoleucel is also approved for the treatment of mantle cell lymphoma (MCL). The results gathered during ZUMA-2 trial showed encouraging responses in heavily pre-treated r/r MCL patients, with CR achieved in 67% after single CAR-T administration [19][12]. Common adverse events following CAR-T therapy occurred in the majority of treated patients, however, they were mostly manageable. A one-year follow-up of the ZUMA-2 trial presented at the 2020 ASH Annual Meeting showed that with a median of 17.5 month-long observations, the CR was maintained in 67% of the patients [26][19].
For the treatment of B cell lymphomas, several CAR-T products are available. Based on JULIET [14][7] and ZUMA-1 [16][9] trials, tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta), respectively, were first to be approved for the treatment of various types of B cell lymphoma, including adult r/r DLBCL, DLBCL arising from follicular lymphoma (FL), or primary mediastinal large B cell lymphoma (PMBCL), for the patients who failed after two or more lines of systemic therapy (see Table 1 for more details). Importantly, long-term follow-up of patients’ status within these trials (median follow-up exceeding 3 years) provided data showing a superior efficacy of Yescarta, with median OS reaching 25.8 months [17][10] as compared to 11.1 months for Kymriah [15][8]. This discrepancy, however, could arise from the fact that most of the patients in the JULIET study received a bridging therapy (e.g., rituximab, nucleoside analogues, corticosteroids), whereas in the ZUMA-1 trial bridging chemotherapy was not allowed, with the exception of corticosteroids administration. Thus, one can speculate that the JULIET trial included more patients with aggressive lymphomas; however, the direct impact of bridging therapies on CAR-T responses should not be excluded.
The year 2021 was extremely rich in FDA/EMA approvals for CAR-T therapies. In addition to the aforementioned Tecartus approval for r/r adult B-ALL, the additional registrations included axicabtagene ciloleucel (Yescarta) for r/r adult FL [18][11], and lisocabtagene maraleucel (Breyanzi) for adult r/r DLBCL, r/r PMBCL, grade 3B FL [21][14]. Moreover, in 2021, it weas witnessed that the first approval of a BCMA-directed CAR-T therapy designated for adult r/r MM patients who had failed at least four previous lines of treatment [24][17]. Indeed, the efficacy of idecabtagene vicleucel (Abecma) was evaluated in the pivotal KarMMa clinical trial [23][16]. Stringent CR (sCR) was detected in only 28%, however, the CAR-T cells were administered to patients with a significant number of prior lines of treatment (median of 6 lines) [24][17]. Importantly, 65% of the patients who achieved sCR had a durable response for at least 12 months. All in all, CAR-T cells targeting BCMA seem to be an attractive treatment option for heavily pre-treated, relapsed MM patients. Certainly, a longer follow-up is still required to estimate the safety profiles and survival rates in a long run.

2. Managing Major Pitfalls of CAR-T Cell Therapy

Despite the phenomenal success of CD19 CAR-T therapy, it is not without limitations and side effects. The challenges faced by CAR-T cell therapy are related to both effector and target cells and include: (1) proliferation, persistence, and exhaustion of CAR-T cells, (2) side effects, (3) immunosuppressive tumor microenvironment, and (4) tumor intrinsic factors that account for the development of resistance.
The obstacles related to effector CAR-T cells are elegantly described by others [27,28,29,30,31][20][21][22][23][24]. Therefore, below it weas only shortly present ed that currently investigated and implemented solutions to modulate insufficient CAR-T cells persistence in vivo, and exhaustion of the effector cells. Considering, however, that more and more data is now gathered on tumor related features contributing to immunotherapy resistance, in this review we where it will mostly focus on limitations and solutions concerning target cells.

2.1. Improvement of CAR-T Cells Persistence

The sufficient number of viable and functional CAR-T cells is one of the major contributors to the therapy’s success [16,32][9][25]. The poor persistence even after the achievement of complete remission is considered to be the main reason for the development of CD19-positive relapses [33,34][26][27]. One of the features affecting CAR-T cell persistence and proneness to exhaustion is the co-stimulatory domain incorporated in the CAR construct. CD28 and 4-1BB are the most frequently exploited co-stimulatory domains in pre-clinically tested and in clinically available CAR products (Table 1). Several sItudies have has been demonstrated that a higher proliferative capacity and longer in vivo persistence of CAR-T cells bearing a 4-1BB domain as compared to CD28 [35,36][28][29]. This effect was at least partly attributed to the 4-1BB-mediated activation of non-canonical nuclear factor κB (ncNF-κB) signaling in CAR-T cells [37][30]; however, as CARs with a CD28 domain exhibit more rapid tumor elimination [38][31], attempts to improve their in vivo performance have led to a generation of mutant CD28 endodomain [39][32], or third generation CARs containing both CD28 and 4-1BB sequences [40][33]. The latter were demonstrated to retain the beneficial aspects of both domains, showing enhanced antitumor activity and concomitantly increased in vivo persistence.
In the clinical settings, in order to improve CAR-T cells persistence and thus the overall therapy efficacy, lymphodepleting chemotherapy is performed prior to CAR-T cells infusion. The pre-conditioning is most often based on fludarabine and/or cyclophosphamide administration. The reason standing behind this approach was demonstrated in several studies showing higher response rates in patients with r/r B-ALL [41[34][35],42], and non-Hodgkin lymphomas, including r/r DLBCL [43[36][37][38],44,45], who received lymphodepleting chemotherapy regimens prior to CD19 CAR-T cells. Primarily, lymphodepletion reduces the numbers of endogenous lymphocytes, which normally absorb the cytokines that stimulate T cells proliferation and thus limit their availability for infused CAR-T cells [44,46][37][39]. In addition, it partially eliminates T regulatory cells (Tregs) which exhibit immunosuppressive activity towards tumor-specific cytotoxic T cells [47][40]. The beneficial effect of lymphodepleting regimens was demonstrated for both CD8-positive and CD4-positive CAR-T cell populations [48][41].
However, the intensity of existing pre-conditioning therapy using fludarabine and cyclophosphamide was shown to be correlated with higher toxicity of the CAR-T cell-based therapy, thus it may exclude the application of this approach for numerous patients [49][42]. The approach of targeted lymphodepletion with a CD45-directed antibody radioconjugate, which was recently shown to eliminate several subsets of leukocytes while preserving progenitor hematopoietic cells in a murine model, could potentially be proposed as a safer alternative [50][43]. However, regardless of the lymphodepleting protocol used, the inevitable side effects of these regimens are lymphopenia and prolonged T cells dysfunction, which may lead not only to overall higher sensitivity to infections and autoimmunity development, but also to tumor relapse [51][44].
Some already existing approaches undermine the need for lymphodepletion. The most prominent is based on the construction of CAR-T cells that besides having the ability to recognize specific targets can also produce selected proteins, in particular cytokines [52][45]. These 4th generation CAR-T cells are called TRUCKs (T cells redirected for antigen-unrestricted cytokine-initiated killing). Cytokines are crucial for CAR-T cells’ survival, proliferation and persistence, both during in vitro culture and following the administration into the patient [53][46]. The additional modification of CD19 CAR-T cells to secrete IL-12 was shown to improve their in vivo cytotoxicity towards murine cells expressing human CD19 and alleviate their suppression by Tregs—the main two aims of pre-conditioning with chemotherapy [54][47]. Similar observations were made by Kueberuwa et al., who demonstrated that CD19 CAR-T cells expressing IL-12 effectively eliminated lymphoma cells in fully lymphorepleted mice [55][48]. Besides the killing of CD19-positive target cells directly, the TRUCKs also contributed to the induction of an anticancer response elicited by the host immune cells, primarily CD8-positive T cells.
Except for IL-12, other cytokines were also shown to improve the persistence and effector functions of transferred cytotoxic T cells. In particular, IL-2, IL-7, and IL-15 supplementation during the culture of CAR-T cells has beneficial effects [56,57][49][50]. Interestingly, CAR-T cells expanded with IL-15 exhibited a higher anticancer efficacy as compared to IL-2-supplemented CD19 CAR-T cells against a lymphoma cell line in vivo [58][51]. In addition, IL-15-expressing CAR-T cells appear to be less terminally differentiated and have an increased ability to expand in vitro, but also tend to be more toxic in vivo due to the simultaneously higher production of TNF-α and IL-2, as compared to CAR-T cells without IL-15 [59][52]. On the other hand, constitutive cytokine expression poses a risk for the uncontrolled growth of administered CAR-T cells which may lead to overt toxicity. Several research groups have demonstrated that novel CAR constructs may be engineered to induce cytokine signaling only after antigen stimulation (5th CAR-T generation) and preserve their superior antitumor effects while having minimal toxicity [60,61,62][53][54][55]. The additional incorporation of an inducible caspase-9-based suicide gene, which mediates the selective depletion of CAR-T cells in case of toxicity, may increase the safety while keeping all the advantages of the therapy based on using anti-CD19 TRUCKs [63,64,65][56][57][58].

2.2. Modulation of CAR-T Cells Exhaustion

The effectiveness of CAR-T cells is also impeded by their exhaustion, which is often caused by the enhanced expression of immune checkpoint molecules on cancer cells and CAR-T cells. In particular, PD-1/PD-L1 interaction activates downstream signaling pathways and inhibits T cell activation, which leads to tumor immune escape [66][59]. PD-L1 was reported to be overexpressed in classical Hodgkin lymphoma [67,68][60][61] and DLBCL [69][62]. Moreover, PD-1 expression was observed to be increased on T cells isolated from B-ALL patients’ bone marrow aspirates [70][63]. Similarly, CD19 CAR-T cells were also reported to have increased PD-1 expression following the infusion to the patients [71][64]. The solution for this issue can be achieved by combining a CAR-based therapy with anti-PD-1 antibodies [72[65][66],73], or their administration just after CAR-T failure [74][67]. The more advanced and safe approaches include the delivery of CAR-T cells secreting anti-PD-1 scFv [75][68], or the transformation of PD-1 in CAR-T cells into a co-stimulatory molecule using the switch-receptor technology [76][69].
Recent reports have also shown that CAR-T cells exhaustion occurs due to epigenetic reprogramming [77,78,79][70][71][72]. In a clinically-relevant setting, Zebley et al. observed the changes in DNA methylation patterns in CD8-positive CD19 CAR-T cells that were previously administered to B-ALL patients [79][72]. Importantly, a deletion of a gene coding DNA methyltransferase 3 alpha (DNMT3A) in T cells bearing CAR constructs augmented a long-term antitumor response and prevented them from developing an exhausted phenotype [77][70]. In addition, several other modifications show promise to limit CAR-T cells exhaustion. For instance, CAR-T cells engineered to overexpress a transcription factor c-Jun had an improved ability to resist exhaustion and maintain functionality despite prolonged activation [80][73].
There are also other factors contributing to the loss of CAR-T cells effector abilities, including those related to CAR tonic signaling [81][74]. One of the consequences of CAR tonic signaling is terminal differentiation to effector cells. The available literature indicates the involvement of sustained phosphoinositide 3-kinase (PI3K)/Akt pathway activation in this process [82,83][75][76]. Therefore, pharmacological approaches aimed at PI3K/Akt signaling inhibition have been implemented during the manufacturing phase to maintain CAR-T cells stemness, including the addition of tyrosine kinase inhibitors, e.g., idelalisib [84][77], ibrutinib [85][78], or duvelisib [86][79]. In addition, the modifications of CAR constructs may be performed to address the issue of CAR tonic signaling and involve several aspects, e.g., the substitution of co-stimulatory domains, alterations in the spacer and hinge domain, or the improvement of scFv stability [81][74]. An alternative approach is to reduce CAR surface expression and selectively switch-off CAR signaling. This could be achieved by incorporating the ligand-induced degradation/destabilizing domain into the C-terminus of the CAR construct [87,88][80][81]. In addition, Weber et al. modulated CAR-T cells exhaustion by the addition of dasatinib, a tyrosine kinase inhibitor that reversed the tonic signaling and led to downregulation of the immune checkpoint markers [88][81]. Importantly, dasatinib administration inhibits the secretion of cytokines by CAR-T cells and impairs their in vivo antitumor activity [89][82]. This effect, however, is reversible after the drug discontinuation, which implies that short-term dasatinib treatment could be used as a switch to control CAR-T cells’ performance.

References

  1. Brentjens, R.J.; Santos, E.; Nikhamin, Y.; Yeh, R.; Matsushita, M.; La Perle, K.; Quintás-Cardama, A.; Larson, S.M.; Sadelain, M. Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2007, 13, 5426–5435.
  2. Milone, M.C.; Fish, J.D.; Carpenito, C.; Carroll, R.G.; Binder, G.K.; Teachey, D.; Samanta, M.; Lakhal, M.; Gloss, B.; Danet-Desnoyers, G.; et al. Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy in vivo. Mol. Ther. J. Am. Soc. Gene Ther. 2009, 17, 1453–1464.
  3. Zhong, X.S.; Matsushita, M.; Plotkin, J.; Riviere, I.; Sadelain, M. Chimeric Antigen Receptors Combining 4–1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell-Mediated Tumor Eradication. Mol. Ther. J. Am. Soc. Gene Ther. 2010, 18, 413–420.
  4. Tokarew, N.; Ogonek, J.; Endres, S.; von Bergwelt-Baildon, M.; Kobold, S. Teaching an Old Dog New Tricks: Next-Generation CAR T Cells. Br. J. Cancer 2019, 120, 26–37.
  5. Maude, S.L.; Laetsch, T.W.; Buechner, J.; Rives, S.; Boyer, M.; Bittencourt, H.; Bader, P.; Verneris, M.R.; Stefanski, H.E.; Myers, G.D.; et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N. Engl. J. Med. 2018, 378, 439–448.
  6. Shah, N.N.; Lee, D.W.; Yates, B.; Yuan, C.M.; Shalabi, H.; Martin, S.; Wolters, P.L.; Steinberg, S.M.; Baker, E.H.; Delbrook, C.P.; et al. Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2021, 39, 1650–1659.
  7. Schuster, S.J.; Bishop, M.R.; Tam, C.S.; Waller, E.K.; Borchmann, P.; McGuirk, J.P.; Jäger, U.; Jaglowski, S.; Andreadis, C.; Westin, J.R.; et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N. Engl. J. Med. 2019, 380, 45–56.
  8. Schuster, S.J.; Tam, C.S.; Borchmann, P.; Worel, N.; McGuirk, J.P.; Holte, H.; Waller, E.K.; Jaglowski, S.; Bishop, M.R.; Damon, L.E.; et al. Long-Term Clinical Outcomes of Tisagenlecleucel in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (JULIET): A Multicentre, Open-Label, Single-Arm, Phase 2 Study. Lancet. Oncol. 2021, 22, 1403–1415.
  9. Neelapu, S.S.; Locke, F.L.; Bartlett, N.L.; Lekakis, L.J.; Miklos, D.B.; Jacobson, C.A.; Braunschweig, I.; Oluwole, O.O.; Siddiqi, T.; Lin, Y.; et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N. Engl. J. Med. 2017, 377, 2531–2544.
  10. Jacobson, C.; Locke, F.L.; Ghobadi, A.; Miklos, D.B.; Lekakis, L.J.; Oluwole, O.O.; Lin, Y.; Hill, B.T.; Timmerman, J.M.; Deol, A.; et al. Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL). Blood 2021, 138, 1764.
  11. Jacobson, C.A.; Chavez, J.C.; Sehgal, A.R.; William, B.M.; Munoz, J.; Salles, G.; Munshi, P.N.; Casulo, C.; Maloney, D.G.; de Vos, S.; et al. Axicabtagene Ciloleucel in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5): A Single-Arm, Multicentre, Phase 2 Trial. Lancet Oncol. 2022, 23, 91–103.
  12. Wang, M.; Munoz, J.; Goy, A.; Locke, F.L.; Jacobson, C.A.; Hill, B.T.; Timmerman, J.M.; Holmes, H.; Jaglowski, S.; Flinn, I.W.; et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N. Engl. J. Med. 2020, 382, 1331–1342.
  13. Shah, B.D.; Ghobadi, A.; Oluwole, O.O.; Logan, A.C.; Boissel, N.; Cassaday, R.D.; Leguay, T.; Bishop, M.R.; Topp, M.S.; Tzachanis, D.; et al. KTE-X19 for Relapsed or Refractory Adult B-Cell Acute Lymphoblastic Leukaemia: Phase 2 Results of the Single-Arm, Open-Label, Multicentre ZUMA-3 Study. Lancet 2021, 398, 491–502.
  14. Abramson, J.S.; Palomba, M.L.; Gordon, L.I.; Lunning, M.A.; Wang, M.; Arnason, J.; Mehta, A.; Purev, E.; Maloney, D.G.; Andreadis, C.; et al. Lisocabtagene Maraleucel for Patients with Relapsed or Refractory Large B-Cell Lymphomas (TRANSCEND NHL 001): A Multicentre Seamless Design Study. Lancet 2020, 396, 839–852.
  15. Abramson, J.S.; Palomba, M.L.; Gordon, L.I.; Lunning, M.A.; Wang, M.; Arnason, J.E.; Purev, E.; Maloney, D.G.; Andreadis, C.; Sehgal, A.R.; et al. Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (Liso-Cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL). Blood 2021, 138, 2840.
  16. Munshi, N.C.; Anderson, L.D.J.; Shah, N.; Madduri, D.; Berdeja, J.; Lonial, S.; Raje, N.; Lin, Y.; Siegel, D.; Oriol, A.; et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N. Engl. J. Med. 2021, 384, 705–716.
  17. Sharma, P.; Kanapuru, B.; George, B.; Lin, X.; Xu, Z.; Bryan, W.W.; Pazdur, R.; Theoret, M.R. FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2022, 21, 3803.
  18. Shah, B.D.; Bishop, M.R.; Oluwole, O.O.; Logan, A.C.; Baer, M.R.; Donnellan, W.B.; O’Dwyer, K.M.; Holmes, H.; Arellano, M.L.; Ghobadi, A.; et al. KTE-X19 Anti-CD19 CAR T-Cell Therapy in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia: ZUMA-3 Phase 1 Results. Blood 2021, 138, 11–22.
  19. Wang, M.; Munoz, J.; Goy, A.H.; Locke, F.L.; Jacobson, C.A.; Hill, B.T.; Timmerman, J.M.; Holmes, H.; Jaglowski, S.; Flinn, I.W.; et al. One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell Lymphoma. Blood 2020, 136, 20–22.
  20. Shah, N.N.; Fry, T.J. Mechanisms of Resistance to CAR T Cell Therapy. Nature reviews. Clin. Oncol. 2019, 16, 372–385.
  21. Brudno, J.N.; Kochenderfer, J.N. Recent Advances in CAR T-Cell Toxicity: Mechanisms, Manifestations and Management. Blood Rev. 2019, 34, 45–55.
  22. Rodriguez-Garcia, A.; Palazon, A.; Noguera-Ortega, E.; Powell, D.J.J.; Guedan, S. CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape. Front. Immunol. 2020, 11, 1109.
  23. Zhylko, A.; Winiarska, M.; Graczyk-Jarzynka, A. The Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies. Cancers 2020, 12, 2030.
  24. Sterner, R.C.; Sterner, R.M. CAR-T Cell Therapy: Current Limitations and Potential Strategies. Blood Cancer J. 2021, 11, 69.
  25. Mueller, K.T.; Maude, S.L.; Porter, D.L.; Frey, N.; Wood, P.; Han, X.; Waldron, E.; Chakraborty, A.; Awasthi, R.; Levine, B.L.; et al. Cellular Kinetics of CTL019 in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia and Chronic Lymphocytic Leukemia. Blood 2017, 130, 2317–2325.
  26. Nie, Y.; Lu, W.; Chen, D.; Tu, H.; Guo, Z.; Zhou, X.; Li, M.; Tu, S.; Li, Y. Mechanisms Underlying CD19-Positive ALL Relapse after Anti-CD19 CAR T Cell Therapy and Associated Strategies. Biomark. Res. 2020, 8, 18.
  27. Gupta, A.; Gill, S. CAR-T Cell Persistence in the Treatment of Leukemia and Lymphoma. Leuk. Lymphoma 2021, 62, 2587–2599.
  28. Kawalekar, O.U.; O’Connor, R.S.; Fraietta, J.A.; Guo, L.; McGettigan, S.E.; Posey, A.D.J.; Patel, P.R.; Guedan, S.; Scholler, J.; Keith, B.; et al. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. Immunity 2016, 44, 380–390.
  29. Zhao, X.; Yang, J.; Zhang, X.; Lu, X.A.; Xiong, M.; Zhang, J.; Zhou, X.; Qi, F.; He, T.; Ding, Y.; et al. Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia. Mol. Ther. Oncol. 2020, 18, 272–281.
  30. Philipson, B.I.; O’Connor, R.S.; May, M.J.; June, C.H.; Albelda, S.M.; Milone, M.C. 4–1BB Costimulation Promotes CAR T Cell Survival through Noncanonical NF-ΚB Signaling. Sci. Signal. 2020, 13, 8248.
  31. Zhao, Z.; Condomines, M.; van der Stegen, S.J.C.; Perna, F.; Kloss, C.C.; Gunset, G.; Plotkin, J.; Sadelain, M. Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. Cancer Cell 2015, 28, 415–428.
  32. Boucher, J.C.; Li, G.; Kotani, H.; Cabral, M.L.; Morrissey, D.; Lee, S.B.; Spitler, K.; Beatty, N.J.; Cervantes, E.V.; Shrestha, B.; et al. CD28 Costimulatory Domain-Targeted Mutations Enhance Chimeric Antigen Receptor T-Cell Function. Cancer Immunol. Res. 2021, 9, 62–74.
  33. Roselli, E.; Boucher, J.C.; Li, G.; Kotani, H.; Spitler, K.; Reid, K.; Cervantes, E.V.; Bulliard, Y.; Tu, N.; Lee, S.B.; et al. 4-1BB and Optimized CD28 Co-Stimulation Enhances Function of Human Mono-Specific and Bi-Specific Third-Generation CAR T Cells. J. Immunother. Cancer 2021, 9, 3354.
  34. Wang, J.; Mou, N.; Yang, Z.; Li, Q.; Jiang, Y.; Meng, J.; Liu, X.; Deng, Q. Efficacy and Safety of Humanized Anti-CD19-CAR-T Therapy Following Intensive Lymphodepleting Chemotherapy for Refractory/Relapsed B Acute Lymphoblastic Leukaemia. Br. J. Haematol. 2020, 191, 212–222.
  35. Fabrizio, V.A.; Boelens, J.J.; Mauguen, A.; Baggott, C.; Prabhu, S.; Egeler, E.; Mavroukakis, S.; Pacenta, H.; Phillips, C.L.; Rossoff, J.; et al. Optimal Fludarabine Lymphodepletion Is Associated with Improved Outcomes after CAR T-Cell Therapy. Blood Adv. 2022, 6, 1961–1968.
  36. Turtle, C.J.; Hanafi, L.-A.; Berger, C.; Hudecek, M.; Pender, B.; Robinson, E.; Hawkins, R.; Chaney, C.; Cherian, S.; Chen, X.; et al. Immunotherapy of Non-Hodgkin’s Lymphoma with a Defined Ratio of CD8+ and CD4+ CD19-Specific Chimeric Antigen Receptor-Modified T Cells. Sci. Transl. Med. 2016, 8, 355ra116.
  37. Hirayama, A.V.; Gauthier, J.; Hay, K.A.; Voutsinas, J.M.; Wu, Q.; Gooley, T.; Li, D.; Cherian, S.; Chen, X.; Pender, B.S.; et al. The Response to Lymphodepletion Impacts PFS in Patients with Aggressive Non-Hodgkin Lymphoma Treated with CD19 CAR T cells. Blood 2019, 133, 1876–1887.
  38. Lyu, C.; Cui, R.; Wang, J.; Mou, N.; Jiang, Y.; Li, W.; Deng, Q. Intensive Debulking Chemotherapy Improves the Short-Term and Long-Term Efficacy of Anti-CD19-CAR-T in Refractory/Relapsed DLBCL with High Tumor Bulk. Front. Oncol. 2021, 11, 706087.
  39. Neelapu, S.S. CAR-T Efficacy: Is Conditioning the Key? Blood 2019, 133, 1799–1800.
  40. Chen, M.L.; Pittet, M.J.; Gorelik, L.; Flavell, R.A.; Weissleder, R.; von Boehmer, H.; Khazaie, K. Regulatory T Cells Suppress Tumor-Specific CD8 T Cell Cytotoxicity through TGF-Beta Signals in vivo. Proc. Natl. Acad. Sci. USA 2005, 102, 419–424.
  41. Watanabe, S.; Arita, M.; Takahashi, M.; Saida, Y.; Koya, T.; Kikuchi, T. Effect of Lymphodepletion on Donor T Cells and the Role of Recipient Cells Persisting after Cytotoxic Treatments in Cancer Immunotherapies. Crit. Rev. Immunol. 2017, 37, 59–73.
  42. Hay, K.A.; Hanafi, L.A.; Li, D.; Gust, J.; Liles, W.C.; Wurfel, M.M.; López, J.A.; Chen, J.; Chung, D.; Harju-Baker, S.; et al. Kinetics and Biomarkers of Severe Cytokine Release Syndrome after CD19 Chimeric Antigen Receptor-Modified T-Cell Therapy. Blood 2017, 130, 2295–2306.
  43. Dawicki, W.; Allen, K.J.H.; Garg, R.; Geoghegan, E.M.; Berger, M.S.; Ludwig, D.L.; Dadachova, E. Targeted Lymphodepletion with a CD45-Directed Antibody Radioconjugate as a Novel Conditioning Regimen Prior to Adoptive Cell Therapy. Oncotarget 2020, 11, 3571–3581.
  44. Williams, K.M.; Hakim, F.T.; Gress, R.E. T Cell Immune Reconstitution Following Lymphodepletion. Semin. Immunol. 2007, 19, 318–330.
  45. Chmielewski, M.; Abken, H. TRUCKS, the Fourth-Generation CAR T Cells: Current Developments and Clinical Translation. Adv. Cell Gene Ther. 2020, 3, e84.
  46. Jin, J.; Cheng, J.; Huang, M.; Luo, H.; Zhou, J. Fueling Chimeric Antigen Receptor T Cells with Cytokines. Am. J. Cancer Res. 2020, 10, 4038–4055.
  47. Pegram, H.J.; Lee, J.C.; Hayman, E.G.; Imperato, G.H.; Tedder, T.F.; Sadelain, M.; Brentjens, R.J. Tumor-Targeted T Cells Modified to Secrete IL-12 Eradicate Systemic Tumors without Need for Prior Conditioning. Blood 2012, 119, 4133–4141.
  48. Kueberuwa, G.; Kalaitsidou, M.; Cheadle, E.; Hawkins, R.E.; Gilham, D.E. CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity. Mol. Ther. Oncol. 2018, 8, 41–51.
  49. Xu, Y.; Zhang, M.; Ramos, C.A.; Durett, A.; Liu, E.; Dakhova, O.; Liu, H.; Creighton, C.J.; Gee, A.P.; Heslop, H.E.; et al. Closely Related T-Memory Stem Cells Correlate with in Vivo Expansion of CAR.CD19-T Cells and Are Preserved by IL-7 and IL-15. Blood 2014, 123, 3750–3759.
  50. Zhang, X.; Lv, X.; Song, Y. Short-Term Culture with IL-2 Is Beneficial for Potent Memory Chimeric Antigen Receptor T Cell Production. Biochem. Biophys. Res. Commun. 2018, 495, 1833–1838.
  51. Alizadeh, D.; Wong, R.A.; Yang, X.; Wang, D.; Pecoraro, J.R.; Kuo, C.F.; Aguilar, B.; Qi, Y.; Ann, D.K.; Starr, R.; et al. IL15 Enhances CAR-T Cell Antitumor Activity by Reducing MTORC1 Activity and Preserving Their Stem Cell Memory Phenotype. Cancer Immunol. Res. 2019, 7, 759–772.
  52. Ataca Atilla, P.; McKenna, M.K.; Tashiro, H.; Srinivasan, M.; Mo, F.; Watanabe, N.; Simons, B.W.; McLean Stevens, A.; Redell, M.S.; Heslop, H.E.; et al. Modulating TNFα Activity Allows Transgenic IL15-Expressing CLL-1 CAR T Cells to Safely Eliminate Acute Myeloid Leukemia. J. Immunother. Cancer 2020, 8, 1229.
  53. Chmielewski, M.; Kopecky, C.; Hombach, A.A.; Abken, H. IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut down Tumor Antigen Expression. Cancer Res. 2011, 71, 5697–5706.
  54. Kagoya, Y.; Tanaka, S.; Guo, T.; Anczurowski, M.; Wang, C.H.; Saso, K.; Butler, M.O.; Minden, M.D.; Hirano, N. A Novel Chimeric Antigen Receptor Containing a JAK-STAT Signaling Domain Mediates Superior Antitumor Effects. Nat. Med. 2018, 24, 352–359.
  55. Štach, M.; Ptáčková, P.; Mucha, M.; Musil, J.; Klener, P.; Otáhal, P. Inducible Secretion of IL-21 Augments Anti-Tumor Activity of PiggyBac-Manufactured Chimeric Antigen Receptor T Cells. Cytotherapy 2020, 22, 744–754.
  56. Hoyos, V.; Savoldo, B.; Quintarelli, C.; Mahendravada, A.; Zhang, M.; Vera, J.; Heslop, H.E.; Rooney, C.M.; Brenner, M.K.; Dotti, G. Engineering CD19-Specific T Lymphocytes with Interleukin-15 and a Suicide Gene to Enhance Their Anti-Lymphoma/Leukemia Effects and Safety. Leukemia 2010, 24, 1160–1170.
  57. Diaconu, I.; Ballard, B.; Zhang, M.; Chen, Y.; West, J.; Dotti, G.; Savoldo, B. Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells. Mol. Ther. J. Am. Soc. Gene Ther. 2017, 25, 580–592.
  58. Guercio, M.; Manni, S.; Boffa, I.; Caruso, S.; Di Cecca, S.; Sinibaldi, M.; Abbaszadeh, Z.; Camera, A.; Ciccone, R.; Polito, V.A.; et al. Inclusion of the Inducible Caspase 9 Suicide Gene in CAR Construct Increases Safety of CAR.CD19 T Cell Therapy in B-Cell Malignancies. Front. Immunol. 2021, 12, 755639.
  59. Sharpe, A.H.; Pauken, K.E. The Diverse Functions of the PD1 Inhibitory Pathway. Nature reviews. Immunology 2018, 18, 153–167.
  60. Roemer, M.G.M.; Advani, R.H.; Ligon, A.H.; Natkunam, Y.; Redd, R.A.; Homer, H.; Connelly, C.F.; Sun, H.H.; Daadi, S.E.; Freeman, G.J.; et al. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2016, 34, 2690–2697.
  61. Cader, F.Z.; Schackmann, R.C.J.; Hu, X.; Wienand, K.; Redd, R.; Chapuy, B.; Ouyang, J.; Paul, N.; Gjini, E.; Lipschitz, M.; et al. Mass Cytometry of Hodgkin Lymphoma Reveals a CD4(+) Regulatory T-Cell-Rich and Exhausted T-Effector Microenvironment. Blood 2018, 132, 825–836.
  62. Xie, W.; Medeiros, L.J.; Li, S.; Yin, C.C.; Khoury, J.D.; Xu, J. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas. Curr. Hematol. Malig. Rep. 2020, 15, 372–381.
  63. Park, S.H.; You, E.; Park, C.-J.; Cho, Y.U.; Jang, S.; Im, H.J.; Seo, J.J.; Park, H.S.; Lee, J.H. Increased Expression of Immune Checkpoint Programmed Cell Death Protein-1 (PD-1) on T Cell Subsets of Bone Marrow Aspirates in Patients with B-Lymphoblastic Leukemia, Especially in Relapse and at Diagnosis. Cytometry. Part B Clin. Cytom. 2020, 98, 336–347.
  64. Brudno, J.N.; Somerville, R.P.T.; Shi, V.; Rose, J.J.; Halverson, D.C.; Fowler, D.H.; Gea-Banacloche, J.C.; Pavletic, S.Z.; Hickstein, D.D.; Lu, T.L.; et al. Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. J. Clin. Oncol. J. Am. Soc. Clin. Oncol. 2016, 34, 1112–1121.
  65. Li, A.M.; Hucks, G.E.; Dinofia, A.M.; Seif, A.E.; Teachey, D.T.; Baniewicz, D.; Callahan, C.; Fasano, C.; McBride, B.; Gonzalez, V.; et al. Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia. Blood 2018, 132, 556.
  66. Cao, Y.; Lu, W.; Sun, R.; Jin, X.; Cheng, L.; He, X.; Wang, L.; Yuan, T.; Lyu, C.; Zhao, M. Anti-CD19 Chimeric Antigen Receptor T Cells in Combination with Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. Front. Oncol. 2019, 9, 767.
  67. Chong, E.A.; Alanio, C.; Svoboda, J.; Nasta, S.D.; Landsburg, D.J.; Lacey, S.F.; Ruella, M.; Bhattacharyya, S.; Wherry, E.J.; Schuster, S.J. Pembrolizumab for B-Cell Lymphomas Relapsing after or Refractory to CD19-Directed CAR T-Cell Therapy. Blood 2022, 139, 1026–1038.
  68. Rafiq, S.; Yeku, O.O.; Jackson, H.J.; Purdon, T.J.; van Leeuwen, D.G.; Drakes, D.J.; Song, M.; Miele, M.M.; Li, Z.; Wang, P.; et al. Targeted Delivery of a PD-1-Blocking ScFv by CAR-T Cells Enhances Anti-Tumor Efficacy in vivo. Nat. Biotechnol. 2018, 36, 847–856.
  69. Liu, H.; Lei, W.; Zhang, C.; Yang, C.; Wei, J.; Guo, Q.; Guo, X.; Chen, Z.; Lu, Y.; Young, K.H.; et al. CD19-Specific CAR T Cells That Express a PD-1/CD28 Chimeric Switch-Receptor Are Effective in Patients with PD-L1-Positive B-Cell Lymphoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2021, 27, 473–484.
  70. Prinzing, B.; Zebley, C.C.; Petersen, C.T.; Fan, Y.; Anido, A.A.; Yi, Z.; Nguyen, P.; Houke, H.; Bell, M.; Haydar, D.; et al. Deleting DNMT3A in CAR T Cells Prevents Exhaustion and Enhances Antitumor Activity. Sci. Transl. Med. 2021, 13, eabh0272.
  71. Gennert, D.G.; Lynn, R.C.; Granja, J.M.; Weber, E.W.; Mumbach, M.R.; Zhao, Y.; Duren, Z.; Sotillo, E.; Greenleaf, W.J.; Wong, W.H.; et al. Dynamic Chromatin Regulatory Landscape of Human CAR T Cell Exhaustion. Proc. Natl. Acad. Sci. USA 2021, 118, 8118.
  72. Zebley, C.C.; Brown, C.; Mi, T.; Fan, Y.; Alli, S.; Boi, S.; Galletti, G.; Lugli, E.; Langfitt, D.; Metais, J.-Y.; et al. CD19-CAR T Cells Undergo Exhaustion DNA Methylation Programming in Patients with Acute Lymphoblastic Leukemia. Cell Rep. 2021, 37, 110079.
  73. Lynn, R.C.; Weber, E.W.; Sotillo, E.; Gennert, D.; Xu, P.; Good, Z.; Anbunathan, H.; Lattin, J.; Jones, R.; Tieu, V.; et al. C-Jun Overexpression in CAR T Cells Induces Exhaustion Resistance. Nature 2019, 576, 293–300.
  74. Ajina, A.; Maher, J. Strategies to Address Chimeric Antigen Receptor Tonic Signaling. Mol. Cancer Ther. 2018, 17, 1795–1815.
  75. Kim, E.H.; Suresh, M. Role of PI3K/Akt Signaling in Memory CD8 T Cell Differentiation. Front. Immunol. 2013, 4, 20.
  76. Caforio, M.; de Billy, E.; De Angelis, B.; Iacovelli, S.; Quintarelli, C.; Paganelli, V.; Folgiero, V. PI3K/Akt Pathway: The Indestructible Role of a Vintage Target as a Support to the Most Recent Immunotherapeutic Approaches. Cancers 2021, 13, 4040.
  77. Stock, S.; Übelhart, R.; Schubert, M.L.; Fan, F.; He, B.; Hoffmann, J.M.; Wang, L.; Wang, S.; Gong, W.; Neuber, B.; et al. Idelalisib for Optimized CD19-Specific Chimeric Antigen Receptor T Cells in Chronic Lymphocytic Leukemia Patients. Int. J. Cancer 2019, 145, 1312–1324.
  78. Fan, F.; Yoo, H.J.; Stock, S.; Wang, L.; Liu, Y.; Schubert, M.L.; Wang, S.; Neuber, B.; Hückelhoven-Krauss, A.; Gern, U.; et al. Ibrutinib for Improved Chimeric Antigen Receptor T-Cell Production for Chronic Lymphocytic Leukemia Patients. Int. J. Cancer 2021, 148, 419–428.
  79. Funk, C.R.; Wang, S.; Chen, K.Z.; Waller, A.; Sharma, A.; Edgar, C.L.; Gupta, V.A.; Chandrakasan, S.; Zoine, J.T.; Fedanov, A.; et al. PI3Kδ/γ Inhibition Promotes Human CART Cell Epigenetic and Metabolic Reprogramming to Enhance Antitumor Cytotoxicity. Blood 2022, 139, 523–537.
  80. Richman, S.A.; Wang, L.C.; Moon, E.K.; Khire, U.R.; Albelda, S.M.; Milone, M.C. Ligand-Induced Degradation of a CAR Permits Reversible Remote Control of CAR T Cell Activity In Vitro and In Vivo. Mol. Ther. J. Am. Soc. Gene Ther. 2020, 28, 1600–1613.
  81. Weber, E.W.; Parker, K.R.; Sotillo, E.; Lynn, R.C.; Anbunathan, H.; Lattin, J.; Good, Z.; Belk, J.A.; Daniel, B.; Klysz, D.; et al. Transient Rest Restores Functionality in Exhausted CAR-T Cells through Epigenetic Remodeling. Science 2021, 372, 1786.
  82. Mestermann, K.; Giavridis, T.; Weber, J.; Rydzek, J.; Frenz, S.; Nerreter, T.; Mades, A.; Sadelain, M.; Einsele, H.; Hudecek, M. The Tyrosine Kinase Inhibitor Dasatinib Acts as a Pharmacologic on/off Switch for CAR T Cells. Sci. Transl. Med. 2019, 11, 5907.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Academic Video Service
Feedback